SMAD3 and colorectal carcinoma: Moreover, CRC patients with high CEACAM1 expression and SMAD3 genomic alterations (heterozygous loss and missense mutations) exhibited a significantly lower 10-year overall survival rate, compared with those in the unaltered group (37% versus 52%) (Fig. 4C).